GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

NCT05130255 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

SCLC
Malignant Melanoma
Sarcoma
High Risk Neuroblastoma

Interventions

DRUG: GD2-SADA:177Lu-DOTA Complex

Sponsor

Y-mAbs Therapeutics